Fullcircle Wealth LLC Invests $371,000 in Becton, Dickinson and Company (NYSE:BDX)

Fullcircle Wealth LLC purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,564 shares of the medical instruments supplier’s stock, valued at approximately $371,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ontario Teachers Pension Plan Board grew its stake in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock worth $451,641,000 after acquiring an additional 68,509 shares during the period. Jennison Associates LLC boosted its stake in Becton, Dickinson and Company by 4.9% in the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after purchasing an additional 18,786 shares during the period. Norden Group LLC boosted its stake in Becton, Dickinson and Company by 2,086.7% in the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after purchasing an additional 49,559 shares during the period. Franklin Street Advisors Inc. NC bought a new position in Becton, Dickinson and Company in the 1st quarter worth about $11,998,000. Finally, Avity Investment Management Inc. boosted its stake in Becton, Dickinson and Company by 3.5% in the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after purchasing an additional 5,527 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.5 %

Shares of BDX traded up $1.08 during mid-day trading on Friday, hitting $236.38. 822,086 shares of the company’s stock traded hands, compared to its average volume of 1,433,813. The company has a quick ratio of 0.97, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $283.50. The firm has a market capitalization of $68.32 billion, a P/E ratio of 52.07, a PEG ratio of 2.06 and a beta of 0.42. The business’s 50-day moving average price is $233.26 and its 200-day moving average price is $236.10.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the previous year, the firm earned $2.96 earnings per share. The business’s revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 13.06 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Insider Activity at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. Citigroup dropped their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI dropped their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Barclays lifted their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.